Objective: To evaluate pneumatic dilatation (PD) for cases of cardiac achalasia as a first-line therapy.
Introduction
Achalasia cardia is one of the common causes of motor dysphagia. Achalasia is characterized by a functional obstruction of the esophagus caused by failed relaxation of the lower esophageal sphincter (LES) in combination with absent peristalsis of the distal esophagus. The exact pathogenesis of this condition remains enigmatic. Pathophysiologically, achalasia cardia is caused by loss of inhibitory ganglion in the myenteric plexus of the esophagus. In the initial stage, degeneration of inhibitory nerves in the esophagus results in unopposed action of excitatory neurotransmitters such as acetylcholine, resulting in high amplitude non-peristaltic contractions (vigorous achalasia); progressive loss of cholinergic neurons over time results in dilation and low amplitude simultaneous contractions in the esophageal body (classic achalasia). 1, 2 The proposed causes for the loss of inhibitory nitrinergic neurons in the esophageal myenteric plexus include genetic inheritance, neuronal degeneration, viral infection and autoimmune disease [3] [4] [5] [6] and the characteristic symptoms of patients with achalasia are dysphagia for solids and liquids, regurgitation of undigested food or saliva, respiratory complaints (nocturnal cough, aspiration), retrosternal pain and weight loss. 7 Therapeutic options aim to improve esophageal emptying by decreasing LES pressure. There are several treatment options, either endoscopic procedures including pneumatic balloon dilatation (PD), Botox injection into the LES, stenting, peroral endoscopic myotomy and surgery (Heller laparoscopic myotomy) can be used for these purposes. 8 Botox injection inhibits the release of acetylcholine in the myenteric plexus, although many prospective studies report swift improvement in symptoms, complaints recurred after 3-12 months, since its effect is short-lived, Botox treatment is recommended only for patients with high comorbidity. 9 One promising new endoscopic procedure is peroral endoscopic myotomy, for which the short-term results available to date of a prospective study have shown improvement in symptoms as no complaints after three months and a significant reduction in resting tone of the LES. 10 Endoscopic sclerotherapy with ethanolamine oleate is a promising alternative to classic therapies for achalasia, but treated patients showed a trend to fibrosis and clinical recurrence so dilation seems particularly effective after endoscopic sclerotherapy. 11 Pneumatic dilatation was chosen as the first-line therapy, despite the wide range of the reported success rates, ranging from 35% to 85% within several years of follow-up. However, these marked differences may be partly explained by differences in the length of follow-up. [12, 13] The current prospective study aimed to determine the outcome of pneumatic dilatation for cases of achalasia of the cardia as a first-line therapy followed by laparoscopic Heller's myotomy in case of failure.
Patients and methods
The current study was conducted at Departments of Otorhinolaryngology and General Surgery, Ain Shams University Hospital, from June 2007 till June 2012. After approval of the study protocol by the Local Ethics Committee and obtaining written fully informed patients' consent, patients with complaints suggestive of having achalasia of the cardia were included in the study and subjected to clinical examination, abdominal ultrasonography and laboratory investigations. Patients who had associated pathology were not enrolled in the study.
Enrolled patients were assessed clinically for disease severity using Valiukenas Achalasia Severity (VAS) scoring system (Table 1) with score = 1-5: mild, 6-9: moderate and P10: severe symptoms. Regurgitation was defined as any sensation of spontaneous (i.e. passive) or active eructation of gastrointestinal contents into the mouth or upper pharynx. 14 All patients underwent complete upper gastrointestinal barium study using a low-density barium sulfate suspension and the stage of the disease was assessed according to the degree of esophageal dilatation according to Kostic et al. 15 as follows: Stage I: minimal esophageal dilatation of <4 cm, Stage II: moderate esophageal dilatation of 4 to 6 cm and Stage III: severe esophageal dilatation of >6 cm.
All patients underwent upper gastrointestinal endoscopy under medazolam (2.5-10 mg) intravenous sedation and after topical lignocaine 10% spray anesthesia. Presence of any resistance at cardia was assessed and biopsy was taken to exclude other pathologies. Manometric studies for determination of the diagnostic manometric findings including absence of esophageal peristalsis, elevated LES pressure >30 mmHg, absent, incomplete, or complete but shortened (<6 s) relaxation of LES and elevated intra-esophageal pressure were carried out.
All patients underwent pneumatic dilatation, ( Fig. 1 ) using 40 mm microvasive balloon under pressure of 15 psi maintained for 60 s to produce a complete disruption of the LES musculature rendering it incompetent so as to release the distal esophageal obstruction and induce symptomatic improvement. To achieve target therapeutic effect, dilatation to a diameter of at least 3 cm was performed using incrementally larger balloon sizes during successive dilatations to lower down the resting LES pressure to 10 mmHg and duration of the procedure was determined. Dilation procedure was conducted as outpatient procedure and patient was observed for 6 h and then oral gastrographin swallow was performed to exclude esophageal perforation. Time of first oral intake without complaint was determined and then, patients were allowed to return home and total hospital stay time was determined. Patients developed intra-procedural complications or failed to be satisfied with their first oral intake were admitted for further management Patients were evaluated clinically for VAS scoring at 1 (M-1), 3 (M-3), 6 (M-6) and 12 (M-12) months after PD. Endoscopic follow-up was conducted at M-1, M-6 and M-12 for Kostic esophageal dilatation (KED) staging. Manometric esophageal pressure (MEP) measurements were performed at M-1, M-3, M-6 and M-12. Patients could not achieve symptomatic relief or had recurrence of symptoms at M-1 were re-evaluated and underwent another PD attempt or referred for surgical interference. Number of PD attempts prior to shift to surgery was recorded and subjective and objective success was evaluated. Patients' outcome at end of 12 months was determined.
Laparoscopic Heller's myotomy combined with Dor fundoplication
All surgeries were conducted under general inhalational anesthesia. After creation of pneumoperitoneum up to an intra- abdominal pressure of 15-mmHg, four-trocar approach was used for conduction of surgery. Myotomy was done for at least 6 cm of distal esophagus and 1.5-2 cm onto the gastric side, the extent and completeness of the myotomy in addition to the integrity of the esophageal mucosa were checked by performing per-operative esophagoscopy to localize the squamocolumnar junction, to assure a widely patent esophagogastric junction, and distend the distal esophagus with air to visualize a bulging mucosa without remaining muscular bands. Dor fundoplication (anterior fundic wrap) as antireflux procedure was performed after completing the myotomy ( Fig. 2a-f ).
Statistical analysis
Obtained data were presented as mean ± SD, ranges, numbers and ratios. 
Results
The study included 35 patients with varied degrees of achalasia; 20 males and 15 females with mean age of 39.5 ± 10.4; range: 23-57 years. According to VAS scoring, only five patients were scored 1, 21 patients were scored 2 and nine patients were scored 3. According to KED staging, seven patients were of stage I, 23 patients were of stage II and five patients were of stage III. Twenty-nine patients had MEP > 45 mmHg, while six patients had esophageal pressure in the range of 30-45 mmHg, (Table 2 ) Mean PD procedural time was <45 min in 25 patients (71.5%), while in 10 patients it ranged between 45 and 60 min. All procedures were completed safely without intraop-erative complications apart from minor mucosal tear recorded in two patients (5.7%), both patients were managed conservatively with broad-spectrum antibiotics and nothing per oral for 24 h to allow mucosal healing. Twenty-seven patients were allowed to take their 1st oral intake within a range of 9-12 h after completion of procedure, while eight patients (22.8%) had their 1st oral intake after more than 12 h. Mean time of hospital stay was 1.3 ± 0.5 days; 25 patients (71.5%) were managed as one-day procedure, while 10 patients required hospitalization and were discharged on the next day, (Table 3) .
Twenty-seven patients (77.1%) showed relief of symptoms till the end of 12-m follow-up period after one PD attempt. On M-1, MEP measurement defined six patients (17.1%) had relapsed elevation of pressure but was in range of 30-45 mmHg and a second PD attempt was carried on. On M-6 MEP measurement, five patients (14.3%); three of those who had their second attempt at M-1 and two new patients had relapsed elevation of MEP but was in the range of 30-45 mmHg and a second PD attempt was carried on for the newly diagnosed patients and a third attempt was carried on for the secondly relapsing patients. Thus, at the end of 12-m follow-up, three patients (8.5%) required three attempts of PD, five patients (14.3%) required two attempts and 27 patients had only one attempt, (Fig. 3) .
At the end of 12-M follow-up period; 26 patients showed sustained complete relief of symptoms and were scored zero on VAS scoring, and had stage I on KED staging. Moreover, all of these 26 patients had mean MEP of 19.2 ± 3.6; range: 14-27 mmHg; thus, PD showed a subjective and objective success rate of 74.4%.
The remaining nine patients had a mean MEP of 32.8 ± 2.2; range: 30-37 mmHg, three patients were scores one on VAS scoring and the other six were scored 2 and on KED staging, all of the nine patients were staged II, (Table  4 , Fig. 4 ). Patients who had failed PD at the end of 12-m Unfortunately, three patients of those had succeeded PD developed reflux esophagitis and planned for laparoscopic anti-reflux surgery. Additionally, the nine patients who had failed PD trials were planned for laparoscopic Heller's myotomy combined with Dor fundoplication. Mean operative time was 103.8 ± 19.4; range: 90-120 min, mean time till first oral intake was 41.1 ± 19.4; range: 18-72 h and mean hospital stay was 2.7 ± 0.8; range: 2-4 days. Two patients had intraoperative mucosal perforation that was immediately repaired and oral intake was prohibited till oral gastrographin swallow assured complete healing of the perforation for an intraoperative complication rate of 16.7% ( Table 5 ).
All of the nine patients who underwent surgical interference for recurrent achalasia were followed up for 12 months and six patients (66.7%) had VAS score of zero, while the other three had VAS score of one. Seven patients were of KED stage I and two patients were of stage II. Moreover, seven patients had mean MEP of 20.6 ± 3.8; range: 15-27 mmHg, while the remaining two patients had mean MEP of 32 and 34 mmHg, respectively, for a subjective surgical success rate of 66.7% and objective success rate of 77.8%.
Comparison of outcome of both modalities showed nonsignificant (v 2 = 0.106, p > 0.05) subjective improvement in favor of PD, while surgery showed non-significant (v 2 = 0.415, p > 0.05) objective improvement compared to PD, (Fig. 5 ). incorporates the fundus, the right crus to the right edge of the myotomy. Arrow 3 points the suture that secures the fundoplication to the diaphragm. Arrow 4 points to the divided short gastric vessels that are brought into an anterior position as the fundoplication is created. This reinforces the need for a complete mobilization of the gastric fundus for the proper configuration of the fundoplication.
Discussion
The current study included 35 patients with well documented achalasia as approved clinically, endoscopically and using esophageal manometry. All patients underwent PD as a firstline therapeutic modality. PD provided significant advantages in the form of the short duration of procedure, 25 patients were managed as one-day procedure and were discharged after oral resumption and conduction of oral gastrographin swallow for assurance of release. Thus, PD provided rapid relief of symptoms and spared the need for anesthesia and surgery with their concomitant hazards with significant reduction of cost and spare of resources. Concerning outcome, PD provided subjective and objective success rate at the end of 12-M follow-up of 74.4% and only nine patients were shifted to surgery and were mostly younger than those had succeeded PD.(See Table 6 ) In line with the obtained results, Boztas et al. 16 found PD is an effective procedure in the treatment of primary achalasia during the short-and long-term period and treatment evaluation can possibly be made objectively with radiographic and manometric alterations of esophagus that occurred after pneumatic dilatation. Honein et al. 17 reported a satisfactory result in 80.5% of their series of achalasia patients after only one or two sessions of PD and concluded that performing balloon dilatation is simple, safe and efficacious for treating patients with achalasia. Chuah et al. 18, 19 evaluated the outcome of 33 achalasia patients managed using PD and reported excellent results in 27 (81.8%), good results in three (9.1%), and failure in three (9.1%) and concluded that the technique is effective and a safe option for achalasia treatment and patients older than 45 years have favorable overall clinical remissions. Sinn et al. 20 reported that a single PD resulted in a 2-year remission rate of 66%. Tanaka et al. 21 also, reported that successful PD was achieved in 41 of 55 (74.5%) patients and concluded that PD is a safe and effective treatment for achalasia, particularly in older patients who experience a better outcome than younger patients.
The reported figure for 12-m follow-up failure rate of PD; 25.6% coincided with Alderliesten et al. 22 who reported 5- Data are presented as numbers; percentages are in parenthesis; P: significance versus baseline data. and 10-year risks of recurrence of 28% and 36% in patients with classic achalasia, respectively and concluded that PD is an effective primary treatment in patients with primary achalasia, but patients are at increased risk of recurrent disease during long-term follow-up, if the disease presented at young age, or they had classic achalasia, high LES pressure 3 months after PD and incomplete obliteration of the balloon's waist during PD.
Comparison of 12-m outcome after either PD or surgical showed non-significant difference between both modalities either subjectively or objectively. These data in addition to the above mentioned advantages of PD indicated the superiority of PD over surgery as a first-line therapeutic modality for classic achalasia. Concerning safety, also there was non-significant difference between both modalities of management.
In support of these findings, Gockel et al. 23 found that PD and laparoscopic myotomy will lead to an immediate and significant improvement in symptoms, although the two treatment modalities did not differ in their subjective results. Kostic et al. 24 reported that only minor differences emerged between PD and laparoscopic myotomy when symptoms, dysphagia scorings, and quality-of-life assessments were evaluated 12 months after initiation of therapy. Also, Chuah et al. 25 documented that the European Achalasia Trial group reported 2year follow-up results indicating that laparoscopic Heller myotomy was not superior to endoscopic PD and although the follow-up period was not long enough to reach a convincing conclusion, it merits the continued use of PD as a generally available technique in gastroenterology. As another evidence for the efficacy of PD, Mikaeli et al. 26 assessed whether botulinum toxin injection before PD is superior to PD alone in achalasia patients and found injection of botulinum toxin before PD does not significantly enhance the efficacy of pneumatic dilatation. Wang et al. 27 evaluated the effect of different approaches in the treatment of achalasia in China and found PD was superior with a lower clinical relapse rate compared to botulinum toxin injection and in uncontrolled trials, the effectiveness of PD was 86.6% (23.9%) versus 94.8% (10.6%) for Heller's Myotomy with the main complications of PD being perforation and gastroesophageal reflux disease.
In conclusion, PD could be considered as safe, effective and cost-effective therapeutic modality for patients having classic achalasia with high subjective and objective success rate. Moreover, PD could spare surgical interference for complicated or recurrent cases and laparoscopic Heller's myotomy with Dor fundoplication is an appropriate surgical modality.
